First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes

@inproceedings{Jurczak2017FirstIH,
  title={First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes},
  author={Wojciech Jurczak and Simon Rule and William Townsend and David Tucker and Martin Dyroff and Barbara Sarholz and J{\"u}rgen S. Scheele and John G Gribben and Pier Luigi Zinzani},
  year={2017}
}
Background: Signaling through the B-cell receptor controls normal cellular B cell functions, but its aberrant function is implicated in oncogenesis in B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBLC). BTK is a key protein involved in transmitting signal from the B-cell receptor. Inhibition of BTK blocks various B-cell functions. The small molecule BTK inhibitor (BTKi) ibrutinib is approved for the treatment of… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.

Novel and emerging therapies for B cell lymphoma

Sabarish Ayyappan, Kami Maddocks
  • Journal of Hematology & Oncology
  • 2019
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED